Novocure to Report Second Quarter 2022 Financial Results

Rhea-AI Summary

Novocure (NASDAQ: NVCR) will report its Q2 2022 financial results on July 28, 2022, prior to U.S. market opening. A conference call will take place at 8 a.m. EDT on the same day to discuss the results. Currently, Novocure is focused on extending survival rates in aggressive cancers through its Tumor Treating Fields technology, approved for glioblastoma and malignant pleural mesothelioma. The company's pipeline includes clinical trials for various cancers, enhancing its global presence and market potential.

Positive

• Ongoing clinical trials for various cancers enhance market potential.
• Current therapies approved for glioblastoma and malignant pleural mesothelioma support revenue generation.

Negative

• None.

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss the company’s financial results for the three and six months ended June 30, 2022, at 8 a.m. EDT on Thursday, July 28, 2022. To access the conference call by phone, use the following registration link, and dial-in details will be provided.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Jersey, and with a growing global footprint, Novocure has regional operating centers in Root, Switzerland, Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 24, 2022 with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220701005077/en/

Investors:

Ingrid Goldberg

investorinfo@novocure.com

610-723-7427

Media:

Leigh Labrie

media@novocure.com

610-723-7428

Source: Novocure

FAQ

When will Novocure report its Q2 2022 financial results?

Novocure will report its Q2 2022 financial results on July 28, 2022.

What time is Novocure's conference call for Q2 2022 results?

The conference call will be held at 8 a.m. EDT on July 28, 2022.

What products does Novocure currently have approved?

Novocure's products are approved for glioblastoma and malignant pleural mesothelioma.

What is Tumor Treating Fields?

Tumor Treating Fields is an innovative therapy developed by Novocure aimed at extending survival in aggressive cancers.

Where can I access Novocure's investor relations information?

Novocure's investor relations information is available on their website at www.novocure.com/investor-relations.